Home › Trials › NCT06380738

Real-world experience of patients with advanced prostate cancer treated with olaparib and abiraterone

A Prospective Observational Study to Evaluate Real-world Clinical Outcomes and Characteristics of Patients With mCRPC Treated With Olaparib + Abiraterone

Observational AstraZeneca · NCT06380738

This study looks at how well the combination of olaparib and abiraterone works for men with advanced prostate cancer who have or haven't been treated with other hormone therapies before.

Quick facts

Study typeObservational
Enrollment250 (estimated)
Ages18 Years and up
SexMale
SponsorAstraZeneca Industry-sponsored
Locations34 sites (Aschaffenburg and 33 other locations)
Trial IDNCT06380738 on ClinicalTrials.gov

What this trial studies

This observational study aims to gather real-world clinical data on patients with metastatic castration-resistant prostate cancer (mCRPC) who are treated with a combination of olaparib and abiraterone. It will assess clinical outcomes in patients who are either naive or previously exposed to novel hormonal agents before starting this treatment. The study will collect demographic and clinical characteristics, as well as treatment history, over a maximum enrollment period of two years, with follow-up extending one year after the last patient is enrolled.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 and older with documented metastatic castration-resistant prostate cancer who are starting treatment with olaparib and abiraterone.

Not a fit: Patients currently participating in a clinical trial with an investigational prostate cancer treatment may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the effectiveness and safety of olaparib combined with abiraterone for patients with mCRPC.

How similar studies have performed: While this study is observational and builds on existing treatments, similar approaches have shown promise in other studies involving mCRPC treatments.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Willing and able to provide written informed consent;
* 18 years of age and above;
* Documented histopathology or cytopathology of PCa, adenocarcinoma;
* Confirmed as mCRPC;
* Initiated olaparib + abiraterone after site activation

Exclusion Criteria:

* Patients participating in a clinical trial with an investigational prostate cancer treatment within 30 days prior to olaparib initiation

Where this trial is running

Aschaffenburg and 33 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Metastatic Castration-resistant Prostate Cancer
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.